Loading...
•
Mar 31
ResMed Q3 2025 Earnings Report
ResMed reported strong Q3 performance with increased revenue, net income, and earnings per share.
Key Takeaways
ResMed delivered a solid third quarter for FY2025, with revenue reaching $1.29 billion, driven by sustained demand across devices, masks, and SaaS offerings. The company saw improvements in gross margins and profitability, supported by efficient operations and favorable product mix.
Revenue grew to $1.29 billion, an 8% increase year-over-year.
Net income rose to $365 million, reflecting robust demand and margin gains.
Adjusted EPS reached $2.37, driven by strong operational performance.
Cash from operations hit $579 million, supported by tax refunds and high profitability.
ResMed
ResMed
ResMed Revenue by Segment
ResMed Revenue by Geographic Location
Revenue by Segment
Total Devices Revenue
CapyFin.comTotal Masks and other Revenue
CapyFin.comRevenue by Geographic Location
U.S., Canada, and Latin America Revenue
CapyFin.comEurope, Asia, and other markets Revenue
CapyFin.com Forward Guidance
ResMed remains focused on expanding its digital health leadership and addressing global sleep and respiratory health challenges, supported by innovation and patient outreach.
Positive Outlook
- Strong ongoing demand for sleep devices and SaaS solutions.
- Margin expansion supported by product mix and efficiencies.
- Robust operating cash flow, enhanced by tax refunds.
- Continued global expansion with new product launches like NightOwl™.
- Positive clinical support for CPAP efficacy strengthens brand value.
Challenges Ahead
- Unfavorable foreign exchange rates partially offset margin gains.
- Rising employee-related and marketing costs impacted SG&A.
- Macroeconomic uncertainties could affect global healthcare spending.
- Limited commentary on future revenue growth rate.
- No quantitative EPS or revenue guidance provided for upcoming quarters.
Revenue & Expenses
Visualization of income flow from segment revenue to net income